Li Fang Xiao

US Patent:

20230008022, Jan 12, 2023

Filed:

Nov 25, 2019

Appl. No.:

17/295497

Inventors:

Dane CLAUSEN - Kenilworth NJ, US
Ping CHEN - Kenilworth NJ, US
Xavier FRADERA - Boston MA, US
Liangqin GUO - Kenilworth NJ, US
Yongxin HAN - Boston MA, US
Shuwen HE - Fanwood NJ, US
Xianhai HUANG - Warren NJ, US
Joseph KOZLOWSKI - Princeton NJ, US
Guoqing LI - Kenilworth NJ, US
Theodore A. MARTINOT - Southborough MA, US
Alexander PASTERNAK - Boston MA, US
Andreas VERRAS - New York NY, US
Li XIAO - Kenilworth NJ, US
Wensheng YU - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 231/56
C07D 491/052
C07D 231/54
A61K 31/496
C07D 401/12
C07D 401/14
C07D 413/12
A61K 31/5377
C07D 498/10
C07D 491/107
C07D 498/08
C07D 471/10
C07D 403/12
C07D 405/12
C07D 498/04
C07D 487/04
C07D 487/10
A61K 31/541
C07D 413/14

Abstract:

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

US Patent:

20210395240, Dec 23, 2021

Filed:

Oct 28, 2019

Appl. No.:

17/287256

Inventors:

Dane CLAUSEN - Kenilworth NJ, US
- Rahway NJ, US
Liangqin Guo - Monroe Township NJ, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Joseph Kozlowski - Princeton NJ, US
Guoqing Li - Belle Mead NJ, US
Theodore A. Martinot - Southborough MA, US
Alexander Pasternak - Jamaica Plain MA, US
David Sloman - Newton MA, US
Li Xiao - Cranbury NJ, US
Wensheng Yu - Edison NJ, US
Rui Zhang - Plainsboro NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 413/14
C07D 401/14

Abstract:

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

US Patent:

20200375987, Dec 3, 2020

Filed:

Dec 20, 2018

Appl. No.:

16/769670

Inventors:

Alexander PASTERNAK - Kenilworth NJ, US
Shuzhi DONG - Kenilworth NJ, US
Jack D. SCOTT - Kenilworth NJ, US
Haiqun TANG - Kenilworth NJ, US
Zhiqiang ZHAO - Kenilworth NJ, US
Dexi YANG - Kenilworth NJ, US
Li XIAO - Kenilworth NJ, US
Xin GU - Scotch Plains NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4985
C07D 487/04
C07D 471/04
A61K 31/4439
A61K 31/519
A61K 31/4188
C07D 513/04
C07D 403/10
A61K 31/4178
A61K 31/407
A61K 31/496
A61K 31/165
A61K 31/7048
A61K 31/546
A61P 31/04

Abstract:

The present invention relates to metallo-β-lactamase inhibitor compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein R, R, and Z are as defined herein. The present invention also relates to compositions which comprise a metallo-β-lactamase inhibitor compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, optionally in combination with a beta lactam antibiotic and/or a beta-lactamase inhibitor. The invention further relates to methods for treating a bacterial infection comprising administering to a patient a therapeutically effective amount of a compound of the invention, in combination with a therapeutically effective amount of one or more β-lactam antibiotics and optionally in combination with one or more beta-lactamase inhibitor compounds. The compounds of the invention are useful in the methods described herein for overcoming antibiotic resistance.